98 results
10-K
2022 FY
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
,” “plan,” “believe,” “estimate,” “may,” “will,” “should,” “could,” “target,” “strategy,” “intend,” “project,” “guidance,” “likely,” “usually,” “potential … commercialization, marketing and manufacturing capabilities and strategy;
our expectations regarding our ability to obtain and maintain intellectual
F-3
OBSVF
ObsEva SA
9 Dec 22
Shelf registration (foreign)
7:06am
positions, business strategy, plans and our objectives for future operations, are forward- looking statements. The words “anticipate,” “believe … and commercialization strategy;
the success, cost, timing and potential indications of our product candidates’ development activities and clinical trials
F-3
EX-4.1
OBSVF
ObsEva SA
9 Dec 22
Shelf registration (foreign)
7:06am
of directors in establishing and reviewing the company’s compensation strategy, guidelines and the performance targets, as well as in preparing the proposals
6-K
EX-99.2
OBSVF
ObsEva SA
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
restructuring and refocus our development and commercialization strategy. We believed these changes were necessary due to the commercial landscape … and refocus our development and commercialization strategy, the Kissei License Agreement was terminated.
Theramex
In February 2022, we entered
6-K
EX-99.1
OBSVF
ObsEva SA
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
and commercialization strategy. The Board of Directors decided to undertake the following actions: (i) give notice of termination of the Company’s license agreement
6-K
ygk4t4aq86h67rthp3w8
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
6-K
3wbgc7u50ygu9ozjl
22 Nov 22
Consent and Amendment Agreement
7:10am
6-K
jfsto8wmo65o8rqj vg
26 Oct 22
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of
5:11pm
6-K
EX-99.1
e1fh8pf
26 Oct 22
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of
5:11pm
6-K
EX-99.1
f8324u h91fq
13 Oct 22
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China
7:13am
6-K
EX-99.1
1o34qy mel
13 Sep 22
ObsEva Announces Progress on Restructuring Initiatives
9:13am
6-K/A
EX-99.1
nvs1udnmg6
13 Sep 22
Index to Unaudited Condensed Consolidated Financial Statements
9:08am
6-K
EX-99.1
ngjmhsv
22 Aug 22
ObsEva Receives Nasdaq Non-Compliance Notice
6:08am
6-K
EX-99.2
vz5qt
17 Aug 22
Index to Unaudited Condensed Consolidated Financial Statements
4:01pm
6-K
1fgek0d
17 Aug 22
Index to Unaudited Condensed Consolidated Financial Statements
4:01pm
6-K
EX-99.1
8fcq8
17 Aug 22
Index to Unaudited Condensed Consolidated Financial Statements
4:01pm
6-K
dimw45b sec
1 Aug 22
ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing
7:21am
6-K
EX-99.1
is8qq okj
1 Aug 22
ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing
7:21am
6-K
EX-99.1
0jcm6g wuob
29 Jul 22
ObsEva Announces Management Change
7:06am
6-K
EX-99.1
s2ubq3nlf d3sbc
27 Jul 22
ObsEva Announces Corporate Updates
7:03am